Beyondspring's Plinabulin Shows Survival Improvement in Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Source: stocktwits
Beyondspring Inc (BYSI) saw a price increase of 10.55% in pre-market trading, reaching a 20-day high. This surge is attributed to the company's recent report on Plinabulin, which demonstrated significant improvements in overall survival rates in clinical trials. The combination of Plinabulin and docetaxel achieved a median overall survival of 15.8 months, compared to 11.7 months for docetaxel alone, indicating a potential advantage for this therapy in patients who have progressed after anti-PD-(L)1 treatment.
The positive results from the DUBLIN-3 study highlight Plinabulin's effectiveness, with a median progression-free survival of 5.6 months and a reduced incidence of brain metastases. These findings suggest that Plinabulin could become a new standard of care for non-small cell lung cancer patients, particularly those with high unmet medical needs. The stock's rise reflects investor confidence in the drug's potential, despite broader market weakness, with the Nasdaq-100 down 0.53% and the S&P 500 down 0.12%.
Overall, the clinical data presented by Beyondspring not only showcases the promising efficacy of Plinabulin but also positions the company favorably in the competitive oncology market. Investors are likely to keep a close eye on further developments and potential regulatory approvals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BYSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BYSI
About BYSI
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BeyondSpring Announces ASCO Poster Presentation for Study 303
- Research Background: BeyondSpring will present its Study 303 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, focusing on patients with 2L/3L non-small cell lung cancer (NSCLC) who progressed on PD-1/PD-L1 inhibitors, showcasing its innovative potential in cancer treatment.
- Presentation Details: The poster will be presented on May 31, 2026, at ASCO, covering the efficacy and immunophenotyping of Plinabulin combined with Docetaxel and Pembrolizumab, which is expected to attract significant attention from industry experts.
- Study Scale: Study 303 is an open-label, single-arm Phase 2 study enrolling 47 patients, with the primary endpoint being investigator-assessed objective response rate (ORR), providing critical data support for BeyondSpring's further development in cancer treatment.
- Funding Support: The study is funded by Merck's Investigator Studies Program and BeyondSpring, highlighting the close collaboration between the two companies in advancing innovative cancer therapies, potentially laying the groundwork for future market expansion.
See More
BeyondSpring Reports Q1 2026 Financial Results
- Financial Overview: BeyondSpring reported a GAAP EPS of -$0.06 for Q1 2026, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of March 31, 2026, the company had $7.9 million in cash, cash equivalents, and short-term investments, suggesting a tight liquidity situation that could limit future operational and investment capabilities.
- Historical Performance Review: Historical earnings data for BeyondSpring indicates that despite current financial pressures, the company has shown profitability in previous quarters, suggesting potential for recovery.
- Future Outlook: The company must implement effective measures to improve its financial condition to bolster market confidence and attract investors, particularly in the current economic climate where liquidity management is crucial.
See More
BeyondSpring to Present New Therapy at AACR Annual Meeting
- Conference Presentation: BeyondSpring will showcase its poster titled 'Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates' at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting the company's ongoing innovation in cancer treatment.
- Presentation Details: The poster will be presented on April 21, 2026, from 2 PM to 5 PM at the San Diego Convention Center, which is expected to attract significant attention from industry experts, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Research Context: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting unmet medical needs in non-small cell lung cancer, showcasing BeyondSpring's potential in cancer therapy.
- Strategic Implications: By presenting at the AACR meeting, BeyondSpring not only demonstrates its research achievements but also strengthens connections with investors and industry experts, paving the way for future collaborations and investment opportunities.
See More
BeyondSpring Files Annual Report for 2025
- Annual Report Submission: BeyondSpring filed its annual report on Form 10-K with the SEC on March 25, 2026, detailing its audited consolidated financial statements for the fiscal year ending December 31, 2025, reflecting the company's progress in clinical-stage biopharmaceutical development.
- Financial Transparency: The annual report is accessible on both the SEC's website and the company's website, ensuring that investors can easily review the company's financial health, thereby enhancing trust between the company and its shareholders.
- Core Asset Development: BeyondSpring's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer, with its unique mechanism aiding in restoring tumor sensitivity to checkpoint inhibitors, showcasing the company's potential to address high unmet medical needs.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements that highlight risks and uncertainties related to future operations, such as challenges in raising necessary funds and potential delays in regulatory approvals, urging investors to consider market competition and the unpredictability of clinical trial outcomes.
See More
BeyondSpring Reports FY 2025 Financial Results
- Financial Overview: BeyondSpring reported a FY 2025 GAAP EPS of -$0.21, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $12.6 million in cash, cash equivalents, and short-term investments, suggesting a buffer in liquidity management but raising concerns about future funding needs.
- Investor Concerns: With ongoing losses and limited cash reserves, BeyondSpring may need to seek additional financing to support its R&D and operations, increasing the risk to future financial stability.
- Market Reaction Expectations: Investors may react cautiously to the earnings report, particularly given the company's lack of profitability, which could lead to stock price volatility and decreased market confidence.
See More
BeyondSpring to Present at IO360° Conference 2026
- Conference Participation: BeyondSpring will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in Boston, showcasing its latest advancements in cancer immunotherapy to enhance its visibility and influence in the biopharmaceutical industry.
- Leadership Presentation: Dr. Lan Huang, Co-Founder and CEO, will present on Plinabulin on February 11 from 4:55 PM to 5:10 PM, highlighting its unique mechanism and clinical development strategy, which is expected to attract attention from investors and industry experts.
- Innovative Mechanism: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting high unmet medical needs in indications like non-small cell lung cancer, demonstrating its potential in cancer treatment.
- Post-Presentation Materials: Following the presentation, the slides will be available on the company's website under the
See More
BeyondSpring Announces ASCO Poster Presentation for Study 303
- Research Background: BeyondSpring will present its Study 303 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, focusing on patients with 2L/3L non-small cell lung cancer (NSCLC) who progressed on PD-1/PD-L1 inhibitors, showcasing its innovative potential in cancer treatment.
- Presentation Details: The poster will be presented on May 31, 2026, at ASCO, covering the efficacy and immunophenotyping of Plinabulin combined with Docetaxel and Pembrolizumab, which is expected to attract significant attention from industry experts.
- Study Scale: Study 303 is an open-label, single-arm Phase 2 study enrolling 47 patients, with the primary endpoint being investigator-assessed objective response rate (ORR), providing critical data support for BeyondSpring's further development in cancer treatment.
- Funding Support: The study is funded by Merck's Investigator Studies Program and BeyondSpring, highlighting the close collaboration between the two companies in advancing innovative cancer therapies, potentially laying the groundwork for future market expansion.
See More
BeyondSpring Reports Q1 2026 Financial Results
- Financial Overview: BeyondSpring reported a GAAP EPS of -$0.06 for Q1 2026, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of March 31, 2026, the company had $7.9 million in cash, cash equivalents, and short-term investments, suggesting a tight liquidity situation that could limit future operational and investment capabilities.
- Historical Performance Review: Historical earnings data for BeyondSpring indicates that despite current financial pressures, the company has shown profitability in previous quarters, suggesting potential for recovery.
- Future Outlook: The company must implement effective measures to improve its financial condition to bolster market confidence and attract investors, particularly in the current economic climate where liquidity management is crucial.
See More
BeyondSpring to Present New Therapy at AACR Annual Meeting
- Conference Presentation: BeyondSpring will showcase its poster titled 'Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates' at the 2026 Annual Meeting of the American Association for Cancer Research, highlighting the company's ongoing innovation in cancer treatment.
- Presentation Details: The poster will be presented on April 21, 2026, from 2 PM to 5 PM at the San Diego Convention Center, which is expected to attract significant attention from industry experts, thereby enhancing the company's visibility in the biopharmaceutical sector.
- Research Context: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting unmet medical needs in non-small cell lung cancer, showcasing BeyondSpring's potential in cancer therapy.
- Strategic Implications: By presenting at the AACR meeting, BeyondSpring not only demonstrates its research achievements but also strengthens connections with investors and industry experts, paving the way for future collaborations and investment opportunities.
See More
BeyondSpring Files Annual Report for 2025
- Annual Report Submission: BeyondSpring filed its annual report on Form 10-K with the SEC on March 25, 2026, detailing its audited consolidated financial statements for the fiscal year ending December 31, 2025, reflecting the company's progress in clinical-stage biopharmaceutical development.
- Financial Transparency: The annual report is accessible on both the SEC's website and the company's website, ensuring that investors can easily review the company's financial health, thereby enhancing trust between the company and its shareholders.
- Core Asset Development: BeyondSpring's lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent for non-small cell lung cancer, with its unique mechanism aiding in restoring tumor sensitivity to checkpoint inhibitors, showcasing the company's potential to address high unmet medical needs.
- Cautionary Note on Forward-Looking Statements: The press release includes forward-looking statements that highlight risks and uncertainties related to future operations, such as challenges in raising necessary funds and potential delays in regulatory approvals, urging investors to consider market competition and the unpredictability of clinical trial outcomes.
See More
BeyondSpring Reports FY 2025 Financial Results
- Financial Overview: BeyondSpring reported a FY 2025 GAAP EPS of -$0.21, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $12.6 million in cash, cash equivalents, and short-term investments, suggesting a buffer in liquidity management but raising concerns about future funding needs.
- Investor Concerns: With ongoing losses and limited cash reserves, BeyondSpring may need to seek additional financing to support its R&D and operations, increasing the risk to future financial stability.
- Market Reaction Expectations: Investors may react cautiously to the earnings report, particularly given the company's lack of profitability, which could lead to stock price volatility and decreased market confidence.
See More
BeyondSpring to Present at IO360° Conference 2026
- Conference Participation: BeyondSpring will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in Boston, showcasing its latest advancements in cancer immunotherapy to enhance its visibility and influence in the biopharmaceutical industry.
- Leadership Presentation: Dr. Lan Huang, Co-Founder and CEO, will present on Plinabulin on February 11 from 4:55 PM to 5:10 PM, highlighting its unique mechanism and clinical development strategy, which is expected to attract attention from investors and industry experts.
- Innovative Mechanism: Plinabulin, as a dendritic cell maturation agent, is in late-stage clinical development targeting high unmet medical needs in indications like non-small cell lung cancer, demonstrating its potential in cancer treatment.
- Post-Presentation Materials: Following the presentation, the slides will be available on the company's website under the
See More
